TEVA Panoramica delle azioni Teva Pharmaceutical Industries Limited sviluppa, produce, commercializza e distribuisce farmaci generici, specialità medicinali e prodotti biofarmaceutici in Nord America, Europa, Israele e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Teva Pharmaceutical Industries Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Teva Pharmaceutical Industries Prezzi storici delle azioni Prezzo attuale dell'azione US$80.25 Massimo di 52 settimane US$84.31 Minimo di 52 settimane US$40.03 Beta 0.80 Variazione di 1 mese 29.44% Variazione a 3 mesi 20.71% Variazione di 1 anno 96.45% Variazione a 3 anni 199.44% Variazione a 5 anni 160.21% Variazione dall'IPO 771.35%
Notizie e aggiornamenti recenti
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01 Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease Jul 25
Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine Jul 18 Vedi altri aggiornamenti
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01 Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease Jul 25
Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine Jul 18
Teva Pharmaceutical Industries Limited to Report Q2, 2024 Results on Jul 31, 2024 Jul 04
Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses Jun 29
Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States Jun 25
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) May 30
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024 May 16 Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024 Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China Apr 11
Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024 Apr 10
Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 Feb 01
Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024 Jan 31
Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents Jan 02
Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity Dec 06
Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business Nov 08
Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder Oct 17
Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023 Oct 07
Teva Announces Changes to Executive Management Team Sep 29
Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023 Aug 05 Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023 Jul 28 Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023
Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study Jul 01
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY Jun 17 Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023 Jun 03
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting May 21
Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States May 16
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023 May 11
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023 Feb 09
Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023 Jan 13
Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million. Dec 06 Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023 Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022
Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims Oct 08 Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022 Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression
Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc Sep 03
Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries Aug 29
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Jul 29
Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022 Jul 28
Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer Jul 02
Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022 Jun 30 Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia May 18
Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022
Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022 Apr 05
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Feb 10
Teva Announces Launch of First-To-Market Generic Version of Narcan (Naloxone Hydrochloride Nasal Spray), in the U.S Dec 23
Teva Pharmaceutical Industries Limited Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims Oct 01
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults Jun 24
Teva Announces Its Launch of the First Generic Perforomist®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States Jun 23 Teva Pharmaceutical Industries Ltd. Presents Analysis on AJOVY® (fremanezumab) Injection
Teva Pharmaceutical Industries Limited Announces the Launch of the First Generic Version of Absorica (Isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States Apr 30
Teva Pharmaceutical Industries Limited Reaffirms Its Earnings Guidance for the Year 2021 Apr 29
Teva to Present New Analyses of AUSTEDO (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting Apr 28
Slater Vecchio LLP Files Lawsuit Against Elmiron Manufacturers After Link with Vision Loss Mar 07
Teva Pharmaceutical Industries Limited Announces New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments Feb 27
Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million. Feb 04
Teva Pharmaceutical Industries Limited Announces Resignation of Gianfranco Nazzi as Executive Vice President – International Markets Commercial, Effective April 30, 2021 Feb 03
Teva Pharmaceutical Industries Limited(TASE:TEVA) dropped from S&P Global BMI Index Jan 28
Teva Pharmaceutical Industries Limited Announces Executive Changes, Effective February 15, 2021 Jan 26
Teva Pharmaceutical Industries Limited to Report Q4, 2020 Results on Feb 10, 2021 Jan 09
Teva Pharmaceuticals Industries Ltd. and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia Jan 08
Rosen Reminds Teva Pharmaceuticals Industries Limited Investors of the Important Deadline Nov 05
Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY (fremanezumab-vfrm) Injection Published in Headache Oct 08 Faruqi &Faruqi, LLP Reminds Investors the Deadline to Seek the Role of Lead Plaintiff in a Federal Securities Class Action Against Teva Pharmaceutical Industries Limited
Pomerantz LLP Announces the Filing of Class Action Against Teva Pharmaceuticals Industries Limited and Certain Officers Sep 24
Teva Pharmaceutical Industries Limited to Report Q2, 2020 Results on Aug 05, 2020 Jul 10 Rendimenti per gli azionisti TEVA IL Pharmaceuticals IL Mercato 7D -2.4% 1.2% 2.6% 1Y 96.5% -2.7% 22.6%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: TEVA ha superato il IL Pharmaceuticals che ha restituito -2.7 % nell'ultimo anno.
Rendimento vs Mercato: TEVA ha superato il mercato IL che ha restituito 22.6 % nell'ultimo anno.
Volatilità dei prezzi Is TEVA's price volatile compared to industry and market? TEVA volatility TEVA Average Weekly Movement 7.1% Pharmaceuticals Industry Average Movement 5.7% Market Average Movement 4.4% 10% most volatile stocks in IL Market 8.7% 10% least volatile stocks in IL Market 3.0%
Prezzo delle azioni stabile: Il prezzo delle azioni di TEVA è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di TEVA è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni IL.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1901 37,000 Richard Francis www.tevapharm.com
Teva Pharmaceutical Industries Limited sviluppa, produce, commercializza e distribuisce farmaci generici, specialità medicinali e prodotti biofarmaceutici in Nord America, Europa, Israele e a livello internazionale. Offre farmaci generici in varie forme di dosaggio, come compresse, capsule, iniettabili, inalanti, liquidi, cerotti transdermici, unguenti e creme; prodotti sterili, ormoni, farmaci ad alta potenza e sostanze citotossiche in forme di dosaggio parenterali e solide; prodotti generici con dispositivi medici e prodotti combinati. L'azienda si concentra sui settori del sistema nervoso centrale (SNC), respiratorio e oncologico.
Mostra di più Teva Pharmaceutical Industries Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Teva Pharmaceutical Industries con la sua capitalizzazione di mercato? TEVA statistiche fondamentali Capitalizzazione di mercato ₪91.40b Guadagni(TTM ) -₪3.51b Ricavi(TTM ) ₪61.30b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) TEVA Conto economico (TTM ) Ricavi US$16.77b Costo del fatturato US$8.41b Profitto lordo US$8.36b Altre spese US$9.32b Guadagni -US$959.00m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
Jan 29, 2025
Utile per azione (EPS) -0.85 Margine lordo 49.84% Margine di profitto netto -5.72% Rapporto debito/patrimonio netto 297.3%
Come si è comportato TEVA nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/02 05:28 Prezzo dell'azione a fine giornata 2025/01/02 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Teva Pharmaceutical Industries Limited è coperta da 59 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Jasper Hellweg Argus Research Company Balaji Prasad Barclays Richard Silver Barclays
Mostra 56 altri analisti 
